---
search:
  boost: .9
---

# Endocrine Agents - Osteoporosis – Bone Ossification Enhancers

[Criteria Document](https://mygainwell-my.sharepoint.com/:w:/g/personal/kaelyn_dobbins_gainwelltechnologies_com/EeqbgCcnhIdIjSpoq5S6YigBs7MDENpq7Ly7d_NSW5yUuQ?e=w8xZ2S){:target="_blank" rel="noopener}

## Criteria { data-search-exclude }

|||
| ---------- | -------------------------------------------------- |
| Criteria 1 | NP - Alendronate Susp, Fosamax Plus D, Risedronate |
| Criteria 2 | Forteo                                             |
| Criteria 3 | Tymlos                                             |

## Non-Preferred Products

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Endocrine Agents: Osteoporosis – Bone Ossification Enhancers</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Non-Preferred Products</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>ALENDRONATE SUSP</td>
<td>053574</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>FOSAMAX PLUS D</td>
<td>058947</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>FOSAMAX PLUS D</td>
<td>062663</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RISEDRONATE</td>
<td>040294</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RISEDRONATE</td>
<td>045102</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RISEDRONATE</td>
<td>050364</td>
<td>GCNSeqNo</td>
</tr>
<tr class="even">
<td></td>
<td>RISEDRONATE</td>
<td>063925</td>
<td>GCNSeqNo</td>
</tr>
<tr class="odd">
<td></td>
<td>RISEDRONATE</td>
<td>066815</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1234</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">365 days</span> with at least <span class="underline">one preferred</span> drug within the same class?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1234</td>
<td></td>
<td>Select and Free Text  </td>
<td><p>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</p>
<p> </p></td>
<td> Y    </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>8</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>9</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

 LENGTH OF AUTHORIZATIONS: 365 Days 

|||
| ------------------ | -------- |
| **Last Approved ** | 5/5/2023 |
| **Other**          |          |

## Forteo

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Endocrine Agents: Osteoporosis – Bone Ossification Enhancers</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Forteo</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th>X</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td></td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>FORTEO</td>
<td>064481</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0998</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1233</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0999</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>1000 </td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">365 days</span> with <span class="underline">one</span> bisphosphonate?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>5</td>
<td>1002</td>
<td></td>
<td>Select </td>
<td>Will the patient’s total lifetime duration of therapy between any parathyroid analog exceed 730 days (2 years)?</td>
<td>Y </td>
<td>1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>6</td>
<td>1233</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y    </td>
<td>1234  </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>7</td>
<td>1234</td>
<td></td>
<td>Select </td>
<td>Will the patient’s total lifetime duration of therapy between any parathyroid analog exceed 730 days (2 years)?</td>
<td>Y </td>
<td>1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>9</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

 LENGTH OF AUTHORIZATIONS: 365 Days 

|||
| ------------------ | -------- |
| **Last Approved ** | 5/5/2023 |
| **Other**          |          |

## Tymlos

<table>
<thead>
<tr class="header">
<th><strong>Criteria Title</strong> </th>
<th>Endocrine Agents: Osteoporosis – Bone Ossification Enhancers</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Criteria Subtitle</strong> </td>
<td>Tymlos</td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td><strong>Approval Level</strong> </td>
<td>GCNSeqNo </td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>Products </strong> </p>
<table>
<thead>
<tr class="header">
<th>Preferred</th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Non-Preferred</td>
<td>X</td>
</tr>
<tr class="even">
<td>Brand</td>
<td></td>
</tr>
<tr class="odd">
<td>Generic</td>
<td></td>
</tr>
<tr class="even">
<td>Other</td>
<td></td>
</tr>
</tbody>
</table></td>
<td>Drug Name  </td>
<td>Corresponding Code (s) </td>
<td>Type of Code (GCNSeqNo, HICL, NDC) </td>
</tr>
<tr class="even">
<td></td>
<td>TYMLOS</td>
<td>077351</td>
<td>GCNSeqNo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr class="header">
<th><strong>Sequence Number </strong></th>
<th><strong>Question ID </strong></th>
<th><strong>Default Next Question ID </strong></th>
<th><strong>Question Type </strong></th>
<th><strong>Question Text </strong></th>
<th><strong>Choice Text </strong></th>
<th><strong>Next Question ID </strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>1 </td>
<td>0997</td>
<td></td>
<td>Select </td>
<td><p>Is the patient new to therapy (initial authorization request) or continuing therapy (re-authorization request)?  </p>
<p>  </p></td>
<td>New Start (initial authorization request)</td>
<td>0998</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Continuation (re-authorization request)  </td>
<td>1233</td>
</tr>
<tr class="odd">
<td>2</td>
<td>0998</td>
<td></td>
<td>Select </td>
<td>Is this request being prescribed in accordance with Food and Drug Administration (FDA) approved labeling?  </td>
<td>Y </td>
<td>0999</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>3</td>
<td>0999</td>
<td> </td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">365 days</span> with at least <span class="underline">one preferred</span> drug within the same class?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1000</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>4</td>
<td>1000 </td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the patient had an inadequate clinical response of at least <span class="underline">365 days</span> with <span class="underline">one</span> bisphosphonate?</p>
<p>If yes, please submit the medication trials and dates.</p></td>
<td>Y </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>1001</td>
</tr>
<tr class="odd">
<td>5</td>
<td>1001</td>
<td></td>
<td>Select and Free Text</td>
<td><p>Has the provider submitted documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances)?</p>
<p>If yes, please submit the medication name and reason for inability to use. </p></td>
<td>Y   </td>
<td>1002</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N   </td>
<td>1236 </td>
</tr>
<tr class="odd">
<td>6</td>
<td>1002</td>
<td></td>
<td>Select</td>
<td><p>Is the request for any of the following:</p>
<p>1) a nonsolid oral dosage formulation</p>
<p>2) a non-preferred extended release formulation</p>
<p>3) a non-preferred brand name that has a preferred generic product</p></td>
<td>Y</td>
<td>1003</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1004</td>
</tr>
<tr class="odd">
<td>7</td>
<td>1003</td>
<td></td>
<td>Select and Free Text</td>
<td>Has the provider submitted documentation of medical necessity for the requested product (i.e. medical reasons for why the patient cannot be changed to a solid oral dosage formulation, inadequate clinical response with a product’s immediate release formulation, or inadequate clinical response or allergy of two or more generic labelers)?</td>
<td>Y</td>
<td>1004</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N</td>
<td>1235</td>
</tr>
<tr class="odd">
<td>8</td>
<td>1004</td>
<td></td>
<td>Select </td>
<td><p>Will the patient’s total lifetime duration of therapy between any parathyroid analog exceed 730 days (2 years)?</p>
<p> </p></td>
<td>Y </td>
<td>1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>9</td>
<td>1233</td>
<td></td>
<td>Select and Free Text  </td>
<td>Has the provider submitted documentation of the patient’s clinical response to treatment and ongoing safety monitoring?</td>
<td>Y    </td>
<td>1234  </td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N    </td>
<td>1235 </td>
</tr>
<tr class="odd">
<td>10</td>
<td>1234</td>
<td></td>
<td>Select </td>
<td><p>Will the patient’s total lifetime duration of therapy between any parathyroid analog exceed 730 days (2 years)?</p>
<p> </p></td>
<td>Y </td>
<td>1235</td>
</tr>
<tr class="even">
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>N </td>
<td>END (Pending Manual Review)</td>
</tr>
<tr class="odd">
<td>11</td>
<td>1235</td>
<td></td>
<td>Free Text</td>
<td>Please provide the rationale for the medication being requested. </td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
<tr class="even">
<td>12</td>
<td>1236</td>
<td></td>
<td>Free Text</td>
<td>Please explain the reason(s) why the patient is unable to use medications not requiring prior approval.</td>
<td>END (Pending Manual Review)</td>
<td></td>
</tr>
</tbody>
</table>

 LENGTH OF AUTHORIZATIONS: 365 Days 

|||
| ------------------ | -------- |
| **Last Approved ** | 5/5/2023 |
| **Other**          |          |
